Programmed Cell Death 1
Showing 1 - 25 of >10,000
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Paclitaxel
- +4 more
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital ( Site 3700)
Jan 31, 2023
PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC
Recruiting
- Non-small Cell Lung Cancer
-
Monza, ItalyASST-Monza Ospedale San Gerardo
Jun 9, 2022
Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)
Withdrawn
- Malignant Melanoma
- tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
- (no location specified)
Nov 12, 2021
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)
Not yet recruiting
- Acute Lymphoblastic Leukemia in Pediatric
- flow cytometric immunophynotyping
-
Sohag, EgyptSohag University Hospital
Jun 19, 2022
Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)
Recruiting
- Donafenib
- Donafenib, PD-1
- TACE
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University,
Mar 4, 2022
Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)
Terminated
- Hodgkin's Lymphoma
- Pembrolizumab
- Umbralisib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 22, 2022
Tumor-Infiltrating Lymphocytes and Programmed Cell Death -
Recruiting
- Breast Cancer
- +2 more
- Observational Study
-
Lucknow, Uttar Pradesh, IndiaSanjay Gandhi Postgraduate Institute of Medical Sciences
Feb 11, 2022
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,
Recruiting
- Advanced Clear Cell Renal Cell Carcinoma
- +3 more
- Aldesleukin
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 5, 2022
Safety of ICIs and TKIs Therapy for HCC
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Lenvatinib Oral Product
- +2 more
-
Wuhan, Hubei, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial
Active, not recruiting
- Hormone-Resistant Prostate Cancer
- +6 more
- Pembrolizumab
- pTVG-HP Plasmid DNA Vaccine
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Nov 8, 2022
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib
Enrolling by invitation
- Hepatocellular Carcinoma Non-resectable
- +3 more
- lenvatinib + sindilimab/carrelizumab
- TACE
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
May 23, 2022
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,
Not yet recruiting
- Muscle-Invasive Bladder Carcinoma
- +2 more
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Aug 3, 2023
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal
Completed
- Colorectal Cancer
- Fruquintinib combined with anti-PD-1 antibodies
-
ChangSha, Hunan, ChinaHunan Cancer Hospital
Aug 27, 2023
Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)
Active, not recruiting
- Metastatic Nonsmall Cell Lung Cancer
- Non Small Cell Lung Cancer
- Stereotactic Body Radiotherapy
-
Philadelphia, PennsylvaniaPhiladelphia CyberKnife
Mar 15, 2022
Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Atezolizumab
- +2 more
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 15, 2022
Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)
Recruiting
- Urothelial Carcinoma
- Zilovertamab vedotin
-
Cleveland, Ohio
- +11 more
Jan 25, 2023
Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and
Recruiting
- Head and Neck Cancer
-
Strasbourg, FranceInstitut de cancérologie Strasbourg Europe
Apr 14, 2022
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite
Completed
- Metastatic Colorectal Adenocarcinoma
- regorafenib plus anti-PD-1 antibodies
-
Changsha, Hunan, ChinaHunan Cancer hospital
Jul 4, 2023
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023